ECKERT & ZIEGLER BG 
By Regulated information
First Quarter 2012 Interim Statement
Seneffe - Belgium, May 3, 2012, Eckert & Ziegler BEBIG (Euronext: EZBG; Reuters: EZBG.BR; Bloomberg: EZBG:BB) has announced today its Interim Statement for the first quarter 2012 ending March 31, 2012.
The Interim Statement report including the milestones of the first quarter 2012 and a selection of consolidated key figures for the 3 months ending March 31, 2012 can be downloaded at:
http://www.bebig.eu/investor_relations/financial_reports/interim_results.html:
http://www.bebig.eu/investor_relations/financial_reports/interim_results.html
Sales for the 1st quarter 2012 reached 7.2 million EUR, compared to 6.7 million EUR in 1st quarter 2011, showing an increase of 6.8%. The main components were income generated by the sales of permanent brachytherapy I-125 (Iodine-125) radiotherapeutic implants as well as income from temporary brachytherapy equipment, i.e. HDR equipment using Co-60 (Cobalt 60) and Ir-192 (Iridium-192) sources (also called "afterloaders").
Earnings before interest and taxes (EBIT) have reached 0.5 million EUR in the 1st quarter 2012, versus 0.7 million EUR in the 1st quarter 2011, showing a decrease of 22.9%.
Net profit reached 0.1 million EUR in the 1st quarter 2012, compared to the net profit of 0.3 million EUR in the 1st quarter 2011. The main impact on the tax position is a planned non deductible charge linked to the purchase of SonoTech.
Total equity of the group stood at 39.2 million EUR on March 31, 2012, versus 39.1 million EUR in December 31, 2011.
Cash amounted to 2.1 million EUR at the end of March 2012, versus 3.1 million EUR in December 2011. The equity to assets ratio stood at 68.1% end of March 2012.
Eckert & Ziegler BEBIG
...Contributing to saving lives!
Eckert & Ziegler BEBIG is a European-based group, active in the medical device sector of the healthcare industry.
Its core business is the treatment of cancer by brachytherapy, a special form of radiotherapy. Eckert & Ziegler BEBIG is a leader in brachytherapy in Europe and is headquartered in Belgium. It has a production facility in Germany and subsidiaries throughout Europe, as well as in India. Eckert & Ziegler BEBIG has also established a worldwide network of distributors and agents to support its product line.
The company's products and equipment are intended for use by oncologists, radiologists, urologists and medical physicists.
Eckert & Ziegler BEBIG employs more than 150 people. It has been listed on the Euronext stock exchange since April 1997 (Euronext: EZBG; Reuters: EZBG.BR; Bloomberg: EZBG: BB).
Contact:
Investor Relations
Tel.: +32 (0) 64 520 808
E-mail: ir@bebig.eu:
mailto:ir@bebig.eu
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.
Source: Eckert & Ziegler BEBIG via Thomson Reuters ONE
